The Netherlands already tested that contradiction
Cayman would not be the first jurisdiction to separate tolerated possession and retail access from lawful production.
For decades, the Netherlands operated Europe’s most visible cannabis market through its coffeeshop system. Small retail transactions were tolerated under strict conditions, but the commercial cultivation and wholesale supply serving those coffeeshops remained illegal.
This became known as the Dutch “backdoor problem.”
Cannabis could leave through the front door in a tolerated sale, but generally had to enter through an illegal supply chain. Regulators could oversee the consumer-facing transaction without legally controlling how the product was cultivated, transported or supplied.
That allowed criminal growers and wholesalers to remain embedded in the market while limiting oversight of product origin, production conditions and quality.
The Dutch government is now attempting to repair that gap through its Controlled Cannabis Supply Chain Experiment. Coffeeshops in participating municipalities are being supplied by designated growers producing regulated, quality-controlled cannabis, while authorities study the effects on crime, safety and public health.
Cayman is not proposing a Dutch-style coffeeshop market. But the underlying lesson remains relevant:
When governments permit possession while refusing to regulate supply, the supply does not disappear. It remains in the shadows.
The product rules must reflect an actual medical market
The commission’s preliminary approach would largely limit decriminalisation to dried cannabis, excluding oils, tinctures, vapes, edibles and other preparations.
That is difficult to reconcile with a functioning medical framework.
Many patients do not want to smoke. Some have respiratory concerns, arthritis, tremors, mobility limitations or little experience using cannabis. Oils, tinctures, capsules, vaporised products and carefully dosed oral preparations may be more practical for those patients when professionally manufactured, tested and clearly labelled.
The regional direction is also evolving. Barbados’ licensed medical system has offered oils, tinctures and pharmaceutical preparations, with its regulator stating that medicinal cannabis flower products were also being introduced.
The issue is not whether Cayman should favour flower or extracts.
It is whether the country intends to create a coherent legal and medical framework or merely decriminalise one form of cannabis while postponing most questions involving patient access, product standards and lawful supply.
Different formats carry different risks. Vapes require stringent manufacturing and contaminant testing. Edibles require controlled doses, clear labelling and packaging that reduces accidental consumption. Flower also requires testing for pesticides, mould, heavy metals and potency.
Those are reasons to regulate products intelligently—not to assume that the raw plant is inherently more appropriate for medicine.
A credible framework should regulate cannabis according to dosage, manufacturing standards, testing, labelling and patient need.
